Kuala Lumpur, 14 October 2021: The latest real-world study for CoronaVac®, the COVID-19 vaccine from established vaccine developer SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), shows that the protection effectiveness of a booster shot using CoronaVac® against COVID-19 and related hospitalisation are notably increased. Effectiveness against symptomatic infection increased from 56% to 80.2% and prevention of hospitalisation increased from 84% to 88%.
Chile was one of the first countries to adopt inactivated coronavirus vaccines for mass vaccination of their population, with SINOVAC supplying all the doses of inactivated virus vaccines. A total of 4.7 million people over the age of 16 years old and who had not previously been infected with COVID-19, have already received two doses of CoronaVac®. Approximately 140,000 of this population were vaccinated with CoronaVac® as a booster, with protection results assessed 14 days after the third dose of vaccination, to monitor the effectiveness against infection and hospitalisation due to COVID-19.
“The results confirmed that people who received a third dose of CoronaVac® can be better protected from infection and hospitalisation. Along with SINOVAC’s Phase III studies and real-world studies from other countries and regions, they continue to highlight CoronaVac® as a well-tolerated, safe and efficacious vaccine.” said Liu Peicheng, spokesperson for SINOVAC. “As part of our commitment to helping to end the pandemic, SINOVAC has already shipped over 2 billion doses of CoronaVac® to over 50 countries around the world, making it the world’s most widely-used COVID-19 vaccine.”
The results of previous large-scale real-world studies in Chile have shown that two doses of CoronaVac®, provide significant protection against COVID-19 infections, COVID-19 related hospitalisation, severe illness, and deaths. Two doses of CoronaVac® were shown to provide 56% efficacy against infection and 84% against hospitalisation, helping to protect people in Chile from COVID-19.
During a press conference on 7 October 2021, Chilean President Piñera stated that all COVID-19 vaccines being used in Chile are safe and effective, significantly reduce infection and hospital admissions, and save many lives. He said that the research results released by the Ministry of Health are "very encouraging" and prove that the implementation of booster vaccination is very effective in reducing the incidence and hospitalisation due to COVID-19.
By the end of September 2021, CoronaVac® had been approved for emergency use by local drug regulatory authorities in nearly 50 countries and regions including emergency use listing by the World Health Organization (WHO) and the African Regulatory Working Group. Since September 2021, CoronaVac® has been used for children vaccination in Chile, Cambodia, Indonesia, Malaysia, and other countries.
The total global supply of CoronaVac® has already exceeded 2 billion doses, with an estimated 1.6 billion doses already administrated worldwide. SINOVAC has become the largest domestic supplier and exporter of China’s COVID-19 vaccine.
